Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor
M. Geurts; D. Gramatzki; S. Merler; M. Duca; F. Girardi; U. T. Sener; D. Roberti; G. Saturno; P. Crivori; A. Montagnoli; L. Mahnke; S. Fu; P. Gaviani; K. A. Jaeckle; J. Zhang; Y. Shi; V. Guarneri; M. Weller; S. H. Kizilbash; M. J. van den Bent; M. Milella; S. Damian AACR-NCI-EORTC International Conference on Molecular […]
Nerviano Medical Sciences Appointed Anders Elm Pedersen, MD, PhD, DMSc, as Senior Medical Director to accelerate further the Global Clinical Development progress
NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead […]
Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development
NERVIANO, IT and BOSTON, Mass, 01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development […]
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO
NERVIANO, IT and BOSTON, Mass, January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor […]
MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer
NEWS MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium […]
NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth
Nerviano, 9 January 2023 NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing […]
NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of NMS-153. A highly potent and selective inhibitor of the MPS1 kinase, NMS-153 is a mitotic […]
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 28 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from […]
Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium […]
NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that […]
